Portolan Capital Management, LLC Castle Biosciences Inc Transaction History
Portolan Capital Management, LLC
- $1.22 Billion
- Q1 2025
A detailed history of Portolan Capital Management, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Portolan Capital Management, LLC holds 1,265,223 shares of CSTL stock, worth $20.2 Million. This represents 2.07% of its overall portfolio holdings.
Number of Shares
1,265,223
Previous 776,579
62.92%
Holding current value
$20.2 Million
Previous $20.7 Million
22.39%
% of portfolio
2.07%
Previous 1.57%
Shares
21 transactions
Others Institutions Holding CSTL
# of Institutions
192Shares Held
26.7MCall Options Held
9.5KPut Options Held
5K-
Black Rock Inc. New York, NY3.04MShares$48.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.05MShares$32.7 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.47MShares$23.4 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.2MShares$19.2 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT998KShares$15.9 Million0.11% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $420M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...